Skip to content
Winnowleaf home

Condition

Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma is a cancer of white blood cells called T cells that settle in the skin, causing patches, plaques, or tumors. Romidepsin, a prescription drug, has the strongest evidence: in two trials of people whose disease had returned or persisted, about a third responded, and 6% had a complete response. Those results apply mostly to advanced or relapsed disease, and most responses were partial.

Sources: PMID 27981793

Supplements studied
0
Medicines and peptides
1
Graded outcomes
2
No supplement studies yetWe haven’t found supplement studies for Cutaneous T-Cell Lymphoma. The medicines and peptides studied for it are listed below.

Prescription medicines and peptides studied, for context

These are not supplements. Most need a prescription, and some are research compounds with no approved use.

1 medicine or peptide

Romidepsin (Istodax)

Romidepsin (Istodax): outcomes studied for Cutaneous T-Cell Lymphoma
GradeOutcomeEffectSizeStudiesPeopleStudies list
Overall Response Rate (CTCL)

Two pivotal Phase 2 trials in relapsed/refractory CTCL (n=71, n=96): ORR 34-35% with 6% CR in both studies. Among 68 patients with advanced disease, 38% achieved response including 5 CRs. Led to FDA approval Nov 2009.

Improves (the measure goes up)Moderate effect5 studies

Studies that measured overall response rate (ctcl)

and 2 more on the Romidepsin (Istodax) page

Pruritus Improvement (CTCL)

43% (28/65) of patients with moderate-severe pruritus at baseline achieved improvement. Important quality of life benefit in CTCL where pruritus is often debilitating.

Improves (the measure goes down)Moderate effect2 studies

Studies that measured pruritus improvement (ctcl)

Key findings

  • Overall Response Rate (CTCL)Romidepsin (Istodax)Improves (the measure goes up)
  • Pruritus Improvement (CTCL)Romidepsin (Istodax)Improves (the measure goes down)

Studies cited

5 studies from PubMed

  1. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphomaCancer Med, 2017 · PMID 27981793
  2. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyJ Clin Oncol, 2012 · PMID 22271479
  3. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011 · PMID 21355097
  4. Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in females with a history of recurrent urinary tract infection: A 6-month multicenter, randomized, double-blind, placebo-controlled trial.Am J Clin Nutr · PMID 39863114
  5. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review.Front Nutr · PMID 39668896